

OFFICE OF THE SECRETARY OF STATE

LAVONNE GRIFFIN-VALADE
SECRETARY OF STATE

CHERYL MYERS
DEPUTY SECRETARY OF STATE
AND TRIBAL LIAISON



ARCHIVES DIVISION

STEPHANIE CLARK
DIRECTOR

800 SUMMER STREET NE
SALEM, OR 97310
503-373-0701

PERMANENT ADMINISTRATIVE ORDER

BP 33-2023

CHAPTER 855
BOARD OF PHARMACY

FILED

12/19/2023 11:53 AM
ARCHIVES DIVISION
SECRETARY OF STATE
& LEGISLATIVE COUNSEL

FILING CAPTION: Adds Vaccination Protocols to Protocol Compendium

EFFECTIVE DATE: 02/01/2024

AGENCY APPROVED DATE: 12/14/2023

CONTACT: Rachel Melvin

971-673-0001

pharmacy.rulemaking@bop.oregon.gov

800 NE Oregon St., Suite 150

Portland, OR 97232

Filed By:

Rachel Melvin

Rules Coordinator

AMEND: 855-020-0300

NOTICE FILED DATE: 10/19/2023

RULE SUMMARY: Amended to add vaccination protocols to the compendium effective 2/1/2024.

CHANGES TO RULE:

855-020-0300

Protocol Compendium

A Pharmacist may prescribe, via statewide drug therapy management protocol and according to rules outlined in this Division, an FDA-approved drug and device listed in the following compendium:¶

(1) Continuation of therapy including emergency refills of insulin (v. 06/2023);¶

(2) Conditions¶

(a) Cough and cold symptom management¶¶

(A) Pseudoephedrine (v. 06/2021);¶¶

(B) Benzonatate (v. 06/2021);¶¶

(C) Short-acting beta agonists (v. 06/2021);¶¶

(D) Intranasal corticosteroids (v. 06/2021);¶¶

(b) Vulvovaginal candidiasis (VVC) (v. 06/2021);¶¶

(c) COVID-19 Antigen Self-Test (v. 12/2021); ¶¶

(3) Preventative care¶¶

(a) Emergency Contraception (v. 06/2021);¶¶

(b) Male and female condoms (v. 06/2021);¶¶

(c) Tobacco Cessation, ~~NRT~~ (Nicotine Replacement Therapy (NRT) and Non-NRT (v. 06/2022);¶¶

(d) Travel Medications (v. 06/2023);¶¶

(e) HIV Post-exposure Prophylaxis (PEP) (v. 06/2023);¶¶

(f) HIV Pre-exposure Prophylaxis (PrEP) (v. 06/2023); ¶¶

(g) Contraception (v. 06/2023); and ¶¶

(gh) ~~Contraception (v. 06/2023)~~ Vaccinations:¶¶

(A) Standard Protocol for All Vaccines: Cover Page & Assessment and Treatment Care Pathway (v. 2/2024); ¶¶

(B) Standard Protocol for All Vaccines: Managing Adverse Reactions (v. 2/2024); ¶¶

(C) Cholera (v. 2/2024); ¶¶

(D) Coronavirus 2019 (v. 2/2024); ¶¶

(E) Haemophilus Influenza type b (v. 2/2024)¶¶

(F) Hepatitis A containing vaccines (v. 2/2024); ¶

(G) Hepatitis B containing vaccines (v. 2/2024); ¶

(H) Human Papillomavirus (v. 2/2024); ¶

(I) Influenza - Inactivated Influenza Vaccines and Recombinant Influenza Vaccines 2023-24 (v. 2/2024); ¶

(J) Influenza - Live Attenuated Influenza Vaccine 2023-24 (v. 2/2024); ¶

(K) Japanese Encephalitis (v. 2/2024); ¶

(L) Meningococcal containing vaccines (v. 2/2024); ¶

(M) Measles Mumps & Rubella containing vaccines (v. 2/2024); ¶

(N) Pneumococcal (v. 2/2024); ¶

(O) Polio (v. 2/2024); ¶

(P) Rabies (v. 2/2024); ¶

(Q) Respiratory Syncytial Virus (v. 2/2024); ¶

(R) Tetanus Diphtheria containing vaccines (v. 2/2024); ¶

(S) Typhoid (v. 2/2024); ¶

(T) Varicella containing vaccines (v. 2/2024); ¶

(U) Yellow fever (v. 2/2024); ¶

(V) Zoster (v. 2/2024); ¶

[Publications referenced are available from the agency.]

Statutory/Other Authority: ORS 689.205

Statutes/Other Implemented: ORS 689.645, ORS 689.649, ORS 689.689, ORS 689.696